<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30530071</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2211-0356</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Multiple sclerosis and related disorders</Title>
          <ISOAbbreviation>Mult Scler Relat Disord</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.</ArticleTitle>
        <Pagination>
          <StartPage>412</StartPage>
          <EndPage>418</EndPage>
          <MedlinePgn>412-418</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.msard.2018.12.002</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-0348(18)30530-3</ELocationID>
        <Abstract>
          <AbstractText>Neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) are inflammatory CNS syndromes mainly involving the optic nerve and/or spinal cord and characterized by the presence of serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). The pathology of NMOSD is complicated, while therapies for NMOSD are limited and only partially effective in most cases. This review article focuses on the main pathology of NMOSD involving AQP4-IgG and lymphocyte function. We also review the existing therapeutic methods and potential new treatments. Experimental NMO animal models are crucial for further research into NMO pathology and treatment. However, no AQP4-IgG-immunized animals have been reported. The establishment of NMO models is therefore difficult and primarily depends on the generation of transgenic mice or transcranial manipulation using human or monoclonal mouse anti-AQP4 antibodies. Advantages and disadvantages of each model are discussed.</AbstractText>
          <CopyrightInformation>Copyright Â© 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xichang Road No.295, Kunming 650000, China. Electronic address: wy4192221@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Lianmei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xichang Road No.295, Kunming 650000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geng</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xichang Road No.295, Kunming 650000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Mult Scler Relat Disord</MedlineTA>
        <NlmUniqueID>101580247</NlmUniqueID>
        <ISSNLinking>2211-0348</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D063308">Myelin-Oligodendrocyte Glycoprotein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063308" MajorTopicYN="N">Myelin-Oligodendrocyte Glycoprotein</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">APC, antigen-presenting cell</Keyword>
        <Keyword MajorTopicYN="N">Abbreviations: ADCC, antibody-dependent cellular cytotoxicity</Keyword>
        <Keyword MajorTopicYN="N">Aqp4, aquaporin 4</Keyword>
        <Keyword MajorTopicYN="N">Aquaporin-4</Keyword>
        <Keyword MajorTopicYN="N">BAFF, b-cell activating factor</Keyword>
        <Keyword MajorTopicYN="N">BBB, blood-brain barrier</Keyword>
        <Keyword MajorTopicYN="N">BCR, b cell receptor</Keyword>
        <Keyword MajorTopicYN="N">CDD, complement-dependent cytotoxicity</Keyword>
        <Keyword MajorTopicYN="N">CFA, complete freund's adjuvant</Keyword>
        <Keyword MajorTopicYN="N">CSF, cerebrospinal fluid</Keyword>
        <Keyword MajorTopicYN="N">CXCL, c-x-c motif chemokine ligand</Keyword>
        <Keyword MajorTopicYN="N">EAE, experimental autoimmune encephalomyelitis</Keyword>
        <Keyword MajorTopicYN="N">ECD, extracellular domain</Keyword>
        <Keyword MajorTopicYN="N">Experimental animal models</Keyword>
        <Keyword MajorTopicYN="N">IGG, immunoglobulin g</Keyword>
        <Keyword MajorTopicYN="N">IVMP, methylprednisolone pulse</Keyword>
        <Keyword MajorTopicYN="N">LETM, longitudinally extensive transverse myelitis</Keyword>
        <Keyword MajorTopicYN="N">MAB, monoclonal antibody</Keyword>
        <Keyword MajorTopicYN="N">MBP, myelin-binding protein</Keyword>
        <Keyword MajorTopicYN="N">MOG, myelin oligodendrocyte glycoprotein</Keyword>
        <Keyword MajorTopicYN="N">MOG-Ab, anti-MOG antibody</Keyword>
        <Keyword MajorTopicYN="N">NF-H, neurofilament heavy chain</Keyword>
        <Keyword MajorTopicYN="N">NMO, neuromyelitis optica</Keyword>
        <Keyword MajorTopicYN="N">NMO-IgG, NMO with serum AQP4-IgG</Keyword>
        <Keyword MajorTopicYN="N">NMOSD, NMO spectrum disorder</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorder</Keyword>
        <Keyword MajorTopicYN="N">PB, plasmablast</Keyword>
        <Keyword MajorTopicYN="N">PP, plasmapheresis</Keyword>
        <Keyword MajorTopicYN="N">Remyelination</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30530071</ArticleId>
        <ArticleId IdType="doi">10.1016/j.msard.2018.12.002</ArticleId>
        <ArticleId IdType="pii">S2211-0348(18)30530-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
